Capricor Therapeutics (CAPR) Research & Development (2016 - 2025)
Historic Research & Development for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $20.4 million.
- Capricor Therapeutics' Research & Development rose 7276.62% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year increase of 5178.76%. This contributed to the annual value of $50.0 million for FY2024, which is 3718.16% up from last year.
- Latest data reveals that Capricor Therapeutics reported Research & Development of $20.4 million as of Q3 2025, which was up 7276.62% from $22.0 million recorded in Q2 2025.
- Capricor Therapeutics' Research & Development's 5-year high stood at $22.0 million during Q2 2025, with a 5-year trough of $2.5 million in Q3 2021.
- Its 5-year average for Research & Development is $9.6 million, with a median of $9.4 million in 2023.
- Over the last 5 years, Capricor Therapeutics' Research & Development had its largest YoY gain of 17500.0% in 2021, and its largest YoY loss of 438.72% in 2021.
- Capricor Therapeutics' Research & Development (Quarter) stood at $4.3 million in 2021, then soared by 44.83% to $6.2 million in 2022, then soared by 59.89% to $9.9 million in 2023, then surged by 46.74% to $14.6 million in 2024, then soared by 39.86% to $20.4 million in 2025.
- Its Research & Development stands at $20.4 million for Q3 2025, versus $22.0 million for Q2 2025 and $14.6 million for Q4 2024.